ArticleScientific reports2026
Conserved mRNA expression patterns of the Klotho family in canine mammary tumors and human breast cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Canine mammary tumors (CMTs) are a naturally occurring comparative model for human breast cancer (HBC) due to their genetic, molecular, and epidemiological similarities. Our previous study in HBC suggested that αKlotho and βKlotho function as tumor suppressors, but γKlotho has an oncogenic effect. Strikingly, we found γKlotho to be overexpressed in more than 65% of triple-negative breast cancer (TNBC) cases. However, the expression and role of Klothos in CMTs have not been investigated. In this study, we analyzed the mRNA expression of the Klotho family, hormone receptors, and FGFRs in 67 fresh-frozen and archived formalin-fixed paraffin-embedded (FFPE) CMTs stratified by histologic subtype. We validated our findings with a publicly available dataset comprising 157 CMTs. Compared with adjacent normal tissue, we found that αKlotho and βKlotho mRNA levels were reduced in CMTs, but γKlotho mRNA expression was increased, with higher levels observed in more aggressive tumors. Differential expression analysis comparing γKlotho-high and -low tumors identified 52 genes that were similarly dysregulated in human and canine datasets, with enrichment in androgen receptor (AR), VEGF, and ERK signaling pathways. The similar expression patterns of Klothos in HBC and CMTs suggest Klothos may have conserved roles in CMT pathogenesis. Further investigation is warranted to determine γKlotho's potential as a prognostic biomarker or therapeutic target in humans and dogs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.